A Novel GIP/Xenin Hybrid Peptide for Type 2 Diabetes (U511)

Monday, 31 October 2016

Type 2 diabetes is a major health concern and current standard-of-care includes secretagogues, sensitizers and more recently, mimics of proteins that interact with insulin.
Type 2 diabetes is a major health for which new drugs are constantly in demand.
The growing market, and the earlier age of onset of the disease makes it necessary to find therapeutic strategies that will be used alone and/or in combination with others to control glycemia over decades and in a safe manner.
Due to the increasing prevalence and progressive nature of type 2 diabetes, there are considerably high unmet needs within the
indication.

Problem Being Solved